JOURNAL OF PRACTICAL HEPATOLOGY ›› 2019, Vol. 22 ›› Issue (4): 526-529.doi: 10.3969/j.issn.1672-5069.2019.04.019

• Nonalcoholic fatty liver diseases • Previous Articles     Next Articles

Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch

Xie Xiao, Liu Ting, Dong Zhixia, et al   

  1. Department of Gastroenterology,First General Hospital,JiaoTong University School of Medicine,Shanghai 200080
  • Received:2018-08-22 Online:2019-07-10 Published:2019-07-19

Abstract: Objective To investigate the value of controlled attenuation parameter (CAP) in diagnosis of individuals with liver steatosis (S) by using Fibrotouch in comparison to liver biopsy.Methods 63 suspected individuals with liver steatosis were enrolled in this study,and all of them received liver biopsies and Fibrotouch measurement for CAP within 2 weeks after liver biopsy. Multiple stepwise regression analysis was used to identify the influencing factors of CAP and establish regressive equation. The receiver operating characteristic(ROC) and the area under ROC(AUROC) were calculated to determine the optimal cut-off value of CAP for diagnosis of liver steatosis.Results Based on liver histopathological examination,the S0 was found in 36(57.1%) and individuals with NAFLD in 27;out of them,we demonstrated S1 in 12(19.1%),S2 in 9(14.3%) and S3 in 6(9.5%),with the CAP of (200.2±21.2) dB/m,(228.7±51.7) dB/m,(259.4±29.1) dB/m and (320.5±22.4) dB/m,respectively;the CAP in individuals with NAFLD was positively correlated to body mass index (BMI,r=0.503,P=0.000) and liver steatosis(r=0.761,P=0.000),and BMI and liver steatosis were the independent predicting factors for CAP;the cut-off-value of CAP in diagnosing S1,S2 and S3 were 212 dB/m,246 dB/m and 287 dB/m,with the sensitivity of 81.5%,86.7% and 100.0% and specificity of 80.6%,91.7% and 96.5%,respectively. Conclusion FibroTouch measurement might help diagnose liver steatosis with high efficacy,which warrants further investigation.

Key words: Non-alcoholic fatty liver disease, Transient elastography, Controlled attenuation parameter, Noninvasive diagnosis